Key Highlights

● Second-quarter Revenue rose by more than a third, aided by the Eucalyptus acquisition.

● The company swung to a net loss and gross Margin fell sharply.

● Full-year revenue and adjusted EBITDA guidance were both raised.

● The next report is due Monday after the close, with a call at five Eastern.

Hims & Hers Health (NYSE:HIMS) reports third-quarter results on Monday after the market closes, and the company enters the print with an unusual mix of signals already on file. Its most recent report, released in the second week of August, showed revenue growing by more than a third, a swing from positive to negative net earnings, a steep drop in gross margin and a raised guidance range for the full year.

Most of the change came from two forces working at once. The company completed the Eucalyptus Acquisition in June, which added a large international revenue stream almost overnight, and it had earlier moved its American weight-loss program toward branded GLP drugs from the compounded versions that previously defined the offering.

When is the next Hims & Hers report and what is the format?

The company announced in mid-October that it will release third-quarter results on Monday after the market closes. A conference call follows at five in the evening Eastern time, with a live audio webcast on the company's website that is archived for a year after the event.

The announcement lists dial-in numbers for callers in the United States and abroad, and separate contacts for stock owners and for the media. No financial figures were pre-announced, and a financial-news aggregator that tracks the company noted that there was no other company news in the days around the announcement.

Because the company has already set formal guidance for the third quarter, Monday's release can be compared directly with the ranges published in August, which is the cleanest way to read the result.

What did the second-quarter report show for Hims & Hers Health?

Revenue for the second quarter was a little above $750 million, up by roughly 38% from a year earlier. Within that, the U.S. Business grew at a mid-teens rate to around $620 million, while the rest-of-world segment jumped to about $130 million from a few million a year earlier, because the Eucalyptus acquisition closed in June.

The company posted a net loss of about $86 million, versus positive net Earnings of roughly $42 million a year before. Adjusted EBITDA was about $60 million, a margin near 8%, compared with a margin of 15% a year earlier.

Gross margin dropped to about 64% from 76%. Free Cash Flow was negative by around $68 million, similar to the year-ago quarter. For the six months, revenue was a little under $1.5 billion, up about a fifth, with a net loss of roughly $180 million.

Why did margins fall so sharply?

The filings point to the weight-loss pivot. In the first quarter the company shifted its U.S. offering toward branded GLP medications, the same approach it takes in other countries, and kept compounded versions on a limited scale. Branded drugs carry a very different cost structure from compounded ones, which tends to lower gross margin even if revenue per customer rises.

Restructuring charges tied to the shift, including inventory write-downs, have also appeared in the statements, totalling about $38 million for the first half. The company separately booked a legal contingency charge of nearly $50 million in the second quarter and excluded it from adjusted EBITDA.

The acquisition added another factor. Newly acquired businesses are typically consolidated at lower margins than the core platform at first, and integration costs, amortization of acquired Assets and compensation tied to continuing employees all appear in the statements.

How many subscribers does the company have?

The release reports roughly 2.9 million subscribers at the end of June, up about 19% from a year earlier. Monthly revenue per average subscriber rose to roughly $92, an increase of more than a fifth.

The two metrics help explain how revenue can grow faster than the subscriber count: customers who move to branded weight-loss programs, or who add multiple products, spend more per month. That same shift is why the company's growth in revenue has outpaced growth in members.

The Quarterly Report lists the focus areas of the business as sexual health, hair loss, hormone health, weight loss, dermatology and mental health, and it notes that non-prescription items are available in tens of thousands of U.S. retail locations.

What guidance did management set?

For the quarter now ending, revenue is guided to a range of about $880 million to $900 million, with adjusted EBITDA in a range of 70-$5 million to $95 million, a margin of roughly 9 to 11%.

For the full year, the company raised its ranges to about three point one to $3.3 billion of revenue and 270-$5 million to $325 million of adjusted EBITDA, a margin of 9 to 10%. It also repeated a long-range aim of at least $6.5 billion of revenue and $1.3 billion of adjusted EBITDA by the end of the decade.

Readers following Growth Stocks will note how often such long-range statements appear in growth companies' releases. They are aspirations, not commitments, and the filing treats them as forward-looking statements subject to the usual caveats.

What did management say in the release?

Chief executive Andrew Dudum said the company has never been better positioned to move faster or go further than it is today. He also described a doctor-led artificial intelligence clinical engine as the basis for rebuilding the consumer health experience.

Chief financial officer Yemi Okupe said domestic revenue growth accelerated to 16% year over year and that the company expects domestic growth to keep accelerating through the second half. That statement is the specific, checkable claim against which Monday's U.S. revenue figure can be compared.

Neither executive's remarks, as reproduced in the release, attached a date to improved margins, and the guidance itself implies margins that stay well below where they were a year ago.

What are the terms of the Eucalyptus deal?

According to the quarterly report, the price paid for accounting purposes was about $970 million, of which roughly $225 million was paid in cash at closing. Deferred payments of about $684 million are due in six quarterly installments over 18 months after closing.

There is also a contingent earn-out of up to roughly $97 million tied to revenue and adjusted EBITDA goals over three fiscal years. The company can settle most deferred and earn-out amounts in Class A stock, subject to a cap of just under 20% of the outstanding class, and no shares were issued at closing.

The acquired business contributed about 5% of consolidated revenue in the second quarter, and the filing says it would have been about 15% on a full-period pro forma basis. It operates a digital health and wellness platform and expands the company's reach in Australia and other markets.

What other acquisitions and international moves are on file?

Earlier in the year the company acquired YourBio, a developer of capillary whole-blood sampling technology, for roughly $150 million including a small contingent payment over five years. That fits the diagnostics ambitions the company mentions in its release.

The quarterly report lists operations in the United States, the United Kingdom, Canada, Germany, Ireland, France, Spain, Australia and Japan. The geographic spread is much wider than a year ago, and it makes foreign currency and local health regulation a larger part of the story.

The platform includes personalization tools, a clinically focused electronic medical record system and digital prescriptions, with American care delivered through affiliated medical groups owned by licensed physicians and through partner pharmacies.

What does the Balance Sheet look like for Hims & Hers Health?

At the end of June, cash and equivalents were about $610 million, with another $230 million in short-term securities. Convertible senior notes, net of issuance costs, stood at roughly $1.37 billion, up from under a billion at the start of the year, after the company raised additional convertible Debt in the first half.

The company paid for capped calls intended to reduce dilution from those notes. The current deferred acquisition payable of about $537 million is a near-term obligation, and Goodwill rose to roughly $1.1 billion from under $300 million at year end.

Taken together, the figures show a balance sheet that is far larger and more leveraged than a year earlier, though the company retains meaningful cash. The filing does not describe any covenant concern.

What legal and regulatory items are mentioned?

The business model depends on state and federal healthcare, privacy and consumer protection rules, and the filings repeat that these laws can change and can affect how the company markets and delivers its services. The weight-loss shift toward branded medicines is, in part, a response to the evolving regulatory and Supply picture.

Readers who need specifics on any particular dispute should consult the full legal proceedings section of the quarterly report rather than rely on summaries.

How could stock-settled payments affect the share count?

The Eucalyptus agreement allows the company to settle most deferred and earn-out amounts in Class A stock rather than cash, up to a cap just below one fifth of the shares outstanding. No shares were issued at closing, so the share count has not yet been affected by that feature.

The choice between cash and stock will matter later. Settling in cash would draw down the Liquidity described above, while settling in stock would dilute existing owners. The filing leaves the decision to the company, within the cap, and the company has not said which route it prefers.

The capped calls the company arranged alongside its convertible notes are designed to offset dilution from the notes, not from acquisition payments, so the two mechanisms address different parts of the capital structure.

How do GAAP and adjusted results differ for this company?

The second quarter illustrates the gap. The company reported a net loss under GAAP, while adjusted EBITDA remained positive at roughly $60 million. The difference reflects items the company excludes from the adjusted measure, including the legal contingency charge, restructuring costs tied to the weight-loss shift, stock-based compensation, Depreciation and amortization of acquired assets.

Excluding such items is common practice among growth companies, but the size of the exclusions matters. When restructuring and legal charges recur, readers may reasonably ask whether they are truly one-time. The filings disclose the amounts, which allows each reader to form a view without relying on management's framing.

Free cash flow is a useful cross-check because it is unaffected by many of those adjustments. It was negative in the second quarter and in the year-earlier quarter alike, a reminder that revenue growth has not yet converted into steady cash generation.

What is the competitive and supply context for weight-loss programs?

Telehealth providers, large pharmacy chains and the drug makers themselves have all been expanding direct-to-consumer routes for weight-loss medicines. That competition is one reason the company has described its offering as a platform that combines prescribing, pharmacy fulfillment and ongoing coaching rather than as a distributor of one drug.

The shift toward branded medicines aligns the U.S. business with how the company already operates in other countries, according to its filings. It also reduces dependence on compounded versions, whose availability has been subject to regulatory debate, though a limited compounded offering remains.

The filings do not quantify how many subscribers use weight-loss programs, so the effect on revenue per subscriber can only be inferred from the monthly revenue figure, which rose by more than a fifth.

Which figures will matter most on Monday?

The first is the U.S. revenue growth rate relative to the 16% reported last time and the management claim of acceleration. The second is total revenue relative to the guided range, which now includes a full quarter of the Eucalyptus business.

The third is gross margin, since a further decline or a stabilization will show how the branded-drug mix is playing out. The fourth is adjusted EBITDA relative to its guided range, and the fifth is free cash flow, which was negative last quarter.

Readers who watch benchmark indexes such as the Nasdaq 100 may note that high-growth healthcare and consumer names often move in sympathy around earnings, but the company's own numbers remain the primary evidence for how it is performing.